Ureteral Stent Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Ureteral Stent Market Trends and Insights

Rising Burden of Urological Disorders

Kidney-stone disease now affects 9.25% of US adults, with the sharpest gains in women under 60—a demographic shift prompting gender-specific stent design refinement.^{[1]Hidar Alibrahim, “Kidney Stone Prevalence Among US Population,” JU Open Plus, journals.lww.com}Obesity-linked metabolic changes accelerate stone formation in younger populations, creating a sustained pipeline of preventive stenting procedures. Chronic kidney disease correlates strongly with retained devices; 30.6% of patients with forgotten stents develop CKD versus 8.3% when timely removal occurs, nudging clinicians toward long-dwell, biocompatible options. These epidemiological realities underpin steady procedural growth and motivate manufacturers to deliver designs that maintain drainage while minimizing encrustation over extended durations.

Ageing Population-Linked Urological Surgeries Surge

Roughly 14.53% of older adults now experience renal stones, yet octogenarian treatment outcomes match younger cohorts, validating ureteroscopy coupled with stenting for frail patients. Initial stone-free rates reach 88% and rise to 97% after ancillary therapy, while complications remain near 9%, reinforcing preference for biodegradable stents that negate second interventions. Frailty assessments show a 1.731-fold greater kidney-stone risk, encouraging preventive drainage strategies for vulnerable seniors. Geriatric urology programs are standardizing anesthesia and recovery protocols to accommodate reduced physiological reserves, positioning temporary, dissolvable implants as a default option.

Increasing Research and Development for Material & Coating Innovations

Advanced coatings such as Percushield and pHreeCoat cut calcium and magnesium adherence relative to traditional Hydroplus layers, directly addressing the 80.8% encrustation prevalence in forgotten stents. FDA draft guidance on chemical analysis tightens biocompatibility testing, accelerating the shift toward low-extractable polymers. Nano-engineered anti-encrustation surfaces show 8.12% CAGR, and drug-eluting designs that release antibiofilm agents are moving from bench to bedside. Radiopaque additives integrated into biodegradable matrices enable clinicians to track in-vivo degradation on routine imaging, solving a prior visibility barrier.

Increased Adoption and Launch of Biodegradable/Bioresorbable Stents

Biodegradable models are expanding at a 10.57% CAGR, proving clinically equivalent while sparing patients the discomfort and cost of removal. PLA and PLA/PHB 3-D-printed geometries allow bespoke sizing for complex anatomies, and regulatory clarity arrived when the FDA recognized ASTM F2579-18 for lactide-based resins. Early tracheal-stent data showing 89.7% two-month effectiveness build confidence for urological adaptation. Liquid-injection molding is scaling production without sacrificing sterility, while combined drug-delivery variants promise simultaneous mechanical relief and localized therapy.

Infection & Encrustation Risks

Encrustation afflicts 80.8% of forgotten stents and drives a 40.2% UTI incidence, while risk escalates from 18.33% at 5 weeks to 75% beyond 12 weeks, underscoring the need for timely exchange or resorbable options. Prolonged pre-operative dwell exceeding two months multiplies post-ureteroscopy infection risk nearly fourfold. Even visually clean devices may harbor internal crystalline blockage, necessitating emergency intervention and prompting R&D toward antimicrobial coatings that disrupt biofilm formation.

Patient Discomfort / Stent-Related Symptoms

Traditional double-J devices cause vesicoureteral reflux in 63% of cases versus none for the RELIEF design, highlighting symptom-relief potential through engineering refinement.^{[3]Ansley Kelm, “The RELIEF Ureteral Stent Secures FDA Clearance,” University Hospitals News, news.uhhospitals.org}Complete intraureteral placement significantly lowers pain scores for normotensive and diabetic cohorts alike. Quality-of-life impacts extend to sexual function, creating adherence challenges unless next-generation devices minimize irritation. Stent-on-string solutions enable patient self-removal and shorten clinic visits, though small dislodgment risks demand careful selection protocols.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Double Pigtail Dominance Faces Biodegradable Challenge

Double pigtail devices retained 39.02% ureteral stents market share in 2025 because clinicians appreciate their reliable drainage and straightforward placement. Yet biodegradable alternatives are growing 10.04% annually as hospitals focus on single-procedure care pathways that boost throughput and patient satisfaction. Open-ended and closed-ended configurations remain niche, reserved for anatomically complex cases or strictures needing directional flow control. Metallic stents serve malignant obstruction needs, with the Allium system delivering 59.5% functional survival and a 22-month median patency despite notable migration. 

Biodegradable innovations address core drawbacks of traditional products. PLA/PGA blends withstand early postoperative forces before dissolving into CO₂ and water, limiting chronic irritation. Hybrid constructs combine self-expanding metal frames with resorbable coverings to unite long-term radial force with eventual lumen restoration. Patient-specific 3-D-printed geometries reduce migration by matching ureteral curvature, aligning with the ureteral stents market trend toward customized therapy at scale.

By Material: Biodegradable Polymers Reshape Traditional Hierarchies

Polyurethane held 41.85% of the ureteral stents market size in 2025 thanks to decades of clinical familiarity and balanced flexibility. However, biodegradable materials exhibit an 10.48% CAGR because payers reward avoidance of second procedures. Silicone continues to dominate extended indwelling cases, valued for smoothness and low encrustation propensity, yet supply-chain shortages of medical-grade grades prompt diversification toward liquid-silicone-rubber variants produced closer to point of care.

Composite designs integrate radiopaque fillers within biodegradable matrices, ensuring visibility without permanent residue. Metal-polymer hybrids exploit nitinol’s elasticity while providing resorbable luminal scaffolding. As ASTM F2579-18 standardization streamlines FDA review, manufacturers accelerate launches, reinforcing a structural change in the ureteral stents market where temporary function replaces permanent implantation.

By Coating/Technology: Anti-Encrustation Innovation Drives Growth

Hydrophilic coatings captured 42.78% revenue in 2025 by easing insertion and lowering friction. Anti-encrustation nano-coatings now expand at 7.83% CAGR, addressing the central pain point of mineral buildup. Early data show Percushield surfaces slashing calcium precipitation, prolonging safe indwelling times without extra systemic antibiotics. Drug-eluting profiles migrate from cardiology, with controlled gentamicin or heparin release targeting infection and thrombosis in situ.

Future-ready designs marry pH-responsive chemistries with intelligent sensors that flag early obstruction signs to cloud-based dashboards. Such convergence mirrors broader ureteral stents market pressures where device makers must pair hardware with data analytics to win procurement contracts emphasizing outcome-based reimbursement.

By Application: Tumor Treatment Emerges as High-Growth Segment

Kidney-stone intervention still delivered 53.10% of ureteral stents market revenue in 2025 because of high prevalence and recurring episodes. Meanwhile, tumor-related drainage shows an 8.35% CAGR as rising cancer survivorship demands durable patency without repeated anesthetic exposure. Post-ureteroscopy recovery benefits from slimline, lubricious stents that reduce hematuria and expedite discharge in ambulatory centers. 

In transplant surgery, biodegradable scaffolds protect delicate anastomoses during vascular reperfusion before vanishing to curb infection. AI-guided sizing tools predict optimal diameter based on CT datasets, lowering post-graft obstruction rates. These advances align with payer preference for evidence-based care, solidifying the ureteral stents market’s evolution toward precision-engineered, condition-specific solutions.

By End User: ASC Growth Reshapes Care Delivery Models

Hospitals commanded 58.92% ureteral stents market share in 2025, yet procedure migration to ambulatory surgical centers is advancing 7.18% per year. Urology-focused ASCs execute 95% of cases under 25 CPT codes, achieving predictable scheduling and reduced overhead. Specialty clinics bridge accessibility gaps, especially in rural areas where hospital urologists are scarce but demand for quick stone relief persists.

Patient-led home-care scenarios emerge as stent-on-string models gain traction, offering self-removal and lowering clinic loads. Reimbursement incentives tied to site neutrality may accelerate this trend, underscoring how care-setting flexibility is integral to future ureteral stents market expansion.

Geography Analysis

North America held 36.85% ureteral stents market share in 2025, powered by robust reimbursement, established procedural pathways, and early adoption of designs such as the RELIEF stent for reflux prevention. Kidney-stone incidence at 9.25% fuels volume, while ASC penetration improves throughput and patient convenience. Regional supply-chain resilience remains top-of-mind after pandemic-era shortages exposed vulnerabilities in medical-grade silicone sourcing.

Asia-Pacific registers the fastest 7.92% CAGR, reflecting healthcare modernization, aging societies in Japan and South Korea, and expanding insurance coverage throughout China and India. Regulatory harmonization across ASEAN lowers approval barriers, and domestic manufacturing plants shorten lead times, making advanced stents accessible to price-sensitive markets. Telemedicine adoption aids post-procedure follow-up across wide geographies, mitigating rural access gaps.

Europe grows steadily under universal healthcare but navigates a complex regulatory landscape that can slow novel-device rollouts. EMA scrutiny of biodegradable-by-product safety imposes rigorous, expensive trials, though academic-center collaborations support evidence generation. Cost-effectiveness remains pivotal; thus, technologies showing tangible savings—such as eliminating removal procedures—gain faster traction. Brexit-related logistics disruption persists, yet established supplier relationships deliver stability.

Regulatory Landscape

Ureteral stents are regulated primarily as medical devices, with pathway selection shifting when coatings incorporate active substances. In the United States, the FDA typically reviews ureteral stents through the 510(k) premarket notification process under its ureteral stent guidance, while drug-eluting variants can be treated as combination products under 21 CFR Part 3, with the lead center determined by the product's primary mode of action.

In Europe, Regulation (EU) 2017/745 (EU MDR) governs ureteral stents as devices, but stents that integrate a medicinal substance with ancillary action trigger additional conformity assessment requirements, including an opinion on the drug component as applicable. Across major markets, biological evaluation expectations are anchored to ISO 10993-1:2025, tightening documentation and strengthening the linkage between risk management and evidence for biocompatibility, extractables, and related safety for both conventional and biodegradable materials.

Value Chain Analysis

The value chain begins with raw materials and component inputs, including medical-grade polymers (polyurethane, silicone, and biodegradable polymers such as PLA/PGA), radiopaque additives, and coating chemistries (hydrophilic, anti-encrustation, and drug-eluting layers). Stent manufacturing commonly involves extrusion and forming, followed by coating application, which remains a key yield and consistency bottleneck for drug-eluting or nano-coated designs. The process then includes assembly with positioning aids, including stent-on-string variants, and ends with terminal sterilization using validated sterile barrier packaging.

Downstream, products typically move through direct sales and specialty distributors to hospitals, ambulatory surgical centers, and specialty urology clinics. Procurement decisions are shaped by clinician preference, outcomes evidence, and supply reliability. Quality and compliance requirements, including FDA QSR and ISO 13485-aligned systems, raise the importance of qualified suppliers for polymers, coating processors, and sterile packaging partners, particularly as the market expands into combination-device configurations where PMOA determination and cross-functional regulatory controls increase development and lifecycle complexity.

Market Opportunities and Future Outlook

Unmet needs around infection, encrustation, and patient discomfort keep product differentiation focused on materials and surface engineering rather than basic form factors. The market also shows whitespace in advanced anti-fouling and controlled-delivery coatings: 2026 academic work described site-specific, microporous hydrogel coatings for tunable drug delivery on ureteral stents (International Journal of Pharmaceutics, March 2026) and an intrinsically disordered protein condensate coating intended to inhibit biofouling and encrustation (Acta Biomaterialia, April 2026). Together, these publications reinforce a pipeline of coating approaches aimed at reducing mineral deposition and bacterial adhesion.

Biodegradable platforms broaden opportunity beyond polymer resorbables into metallic biodegradation concepts, supported by 2026 in vitro evaluation of Mg-1Y biodegradable ureteral stent prototypes (npj Materials Degradation, July 2026). Beyond device design, a commercialization gap persists in standardized, physiologically realistic in vitro test systems that reproduce urinary flow, temperature, and microbial conditions. Developers that industrialize these validation platforms can improve comparability across designs and streamline evidence generation for regulatory submissions and hospital value assessments.